Effect of Long-Term Exposure to Lower Low-Density Lipoprotein Cholesterol Beginning Early in Life on the Risk of Coronary Heart Disease

Cited by (901)

Items 401–500 of 901

1. Why do statins reduce cardiovascular disease more than other lipid modulating therapies?
   Catherine Mary Schooling, Shiu Lun Au Yeung, Gabriel Matthew Leung · 2014 · European Journal of Clinical Investigation
2. Vitamin D, parathyroid hormone and risk factors for coronary artery disease in an elderly Chinese population
   Wei R. Chen, Yun D. Chen, Yang Shi, Da Wei Yin, Hao Wang, Yuan Sha · 2014 · Journal of Cardiovascular Medicine
3. Predicting the Direction of Causal Effect Based on an Instrumental Variable Analysis: A Cautionary Tale
   Stephen Burgess, Dylan S. Small · 2016 · Journal of Causal Inference
4. Cost-effectiveness of Ezetimibe plus statin lipid-lowering therapy: A systematic review and meta-analysis of cost-utility studies
   Akhil Sasidharan, Sajith Kumar S, Kayala Venkata Jagadeesh, Meenakumari Natarajan, Bhavani Shankara Bagepally · 2022 · PLoS ONE
5. Eradicating Atherosclerosis: Should We Start Statins at Younger Ages and at Lower LDL-Cs
   T E O'Toole, Michelle D. Kelsey, Nishant P. Shah, Robert W. McGarrah, Neha Jadeja Pagidipati · 2022 · Current Cardiology Reports
6. Dyslipidaemia in the elderly: to treat or not to treat?
   Niki Katsiki, Genovefa D. Kolovou, Pablo Pérez‐Martínez, Dimitri P. Mikhailidis · 2018 · Expert Review of Clinical Pharmacology
7. Recent Advances in Understanding the Pathogenesis of Cardiovascular Diseases and Development of Treatment Modalities
   Rahul Mittal, Vasanti M. Jhaveri, Sae-In Samantha Kay, Aubrey B. Greer, Kyle J. Sutherland, Hannah Stowe McMurry, Nicole Lin, Jeenu Mittal, Arul K. Malhotra, Amit P. Patel · 2018 · Cardiovascular & Haematological Disorders - Drug Targets
8. Pediatric Obesity, Hypertension, Lipids
   Scott Leopold, Justin P.V. Zachariah · 2020 · Current Treatment Options in Pediatrics
9. Higher Responsiveness to Rosuvastatin in Polygenic versus Monogenic Hypercholesterolemia: A Propensity Score Analysis
   Agnieszka Mickiewicz, Marta Futema, Agnieszka Ćwiklińska, Agnieszka Kuchta, Maciej Jankowski, Mariusz F. Kaszubowski, Magdalena Chmara, Bartosz Wasąg, Marcin Fijałkowski, Milosz Jaroslaw Jaguszewski et al. · 2020 · Life
10. The promise and reality of therapeutic discovery from large cohorts
    Eugene Melamud, D. Leland Taylor, Anurag Sethi, Madeleine Cule, Anastasia Baryshnikova, Danish Saleheen, Nick van Bruggen, Garret A. FitzGerald · 2020 · Journal of Clinical Investigation
11. Genomic Medicine for Improved Prediction and Primordial Prevention of Cardiovascular Disease
    George Thanassoulis, Gina Marie Peloso, Christopher J. O’Donnell · 2013 · Arteriosclerosis Thrombosis and Vascular Biology
12. Perspective on Trends in Statin Use
    William S. Weintraub · 2016 · JAMA Cardiology
13. Vaccination to prevent atherosclerotic cardiovascular diseases
    Ulrich Laufs, Brian A. Ference · 2017 · European Heart Journal
14. Functional foods and nutraceuticals in the treatment of hypercholesterolemia: Statement of the Spanish Society of Arteriosclerosis 2023
    Pablo Pérez‐Martínez, Emilio Ros, Juan Pedro‐Botet, Fernando Civeira, Vicente Pascual, Cármen Garcés, Rosa Solà, Francisco Pérez‐Jiménez, José María Mostaza · 2023 · Clínica e Investigación en Arteriosclerosis (English Edition)
15. Investigating linear and nonlinear associations of LDL cholesterol with incident chronic kidney disease, atherosclerotic cardiovascular disease and all-cause mortality: A prospective and Mendelian randomization study
    Zhenqian Wang, Xiao Yang, Jiawen Lu, Chenfeng Zou, Wenyu Huang, Jiaying Zhang, SiYang Maggie Liu, Liyuan Han, Feng Jiao, Dechao Tian et al. · 2023 · Atherosclerosis
16. Efficacy of oats in dyslipidemia: a systematic review and meta-analysis
    Anqi Li, Jing Gao, Yingcai Li, Shihao Qi, Tiantian Meng, Shanshan Yu, Yuqing Zhang, Qingyong He · 2024 · Food & Function
17. Effectiveness of treat-to-target cholesterol-lowering interventions on cardiovascular disease and all-cause mortality risk in the community-dwelling population: a target trial emulation
    Zhao Yang, Qiujv Deng, Yongchen Hao, Na Yang, Lizhen Han, Pingping Jia, Pan Zhou, Yiming Hao, Ziyu Wang, Wenyan Zhao et al. · 2024 · Nature Communications
18. The year in cardiology 2015: prevention
    M. John Chapman, Stefan Blankenberg, Ulf Landmesser · 2016 · European Heart Journal
19. Proprotein convertase subtilisin kexin type 9 inhibitors: update from clinical trials to real-world experience
    Michel Farnier · 2016 · Current Opinion in Lipidology
20. Separating the direct effects of traits on atherosclerotic cardiovascular disease from those mediated by type 2 diabetes
    Venexia M. Walker, Marijana Vujković, Alice R Carter, Neil M Davies, Miriam S. Udler, Michael G. Levin, George Davey Smith, Benjamin F. Voight, Tom R. Gaunt, Scott M. Damrauer · 2022 · Diabetologia
21. Pediatric Lipid Management
    J. Zachariah, Philip K. Johnson · 2014 · Endocrinology and metabolism clinics of North America (Print)
22. Clinical observations and treatment of pediatric homozygous familial hypercholesterolemia due to a low-density lipoprotein receptor defect
    Cheng-Hung Huang, Pao‐Chin Chiu, Haochuan Liu, Yung-Hsiu Lu, Junkai Huang, Min‐Ji Charng, Dau‐Ming Niu · 2014 · Journal of clinical lipidology
23. Effect of dietary modification by calorie restriction on cholesterol levels in lipoprotein(a) and other lipoprotein classes
    Yuji Hirowatari, Daisuke Manita, Keiko Kamachi, Akira Tanaka · 2016 · Annals of Clinical Biochemistry International Journal of Laboratory Medicine
24. Precision Medicine and Cardiovascular Health: Insights from Mendelian Randomization Analyses
    Wes Spiller, Keum Ji Jung, Ji‐Young Lee, Sun Ha Jee · 2019 · Korean Circulation Journal
25. The burden of cholesterol accumulation through the lifespan: why pharmacological intervention should start earlier to go further?
    Alberto Zambon, Alberto Mello e Silva, Michel Farnier · 2020 · European Heart Journal - Cardiovascular Pharmacotherapy
26. Mapping Hyperlipidemia in Young Adulthood to Coronary Risk
    Seth Shay Martin, Erin D. Michos · 2015 · Circulation
27. HOPS: a quantitative score reveals pervasive horizontal pleiotropy in human genetic variation is driven by extreme polygenicity of human traits and diseases
    Daniel M. Jordan, Marie Verbanck, Ron Do · 2018 · bioRxiv (Cold Spring Harbor Laboratory)
28. White blood cells and coronary heart disease: A mendelian randomization study
    Qiuping Zhao, Rongmei Liu, Hui Chen, Xiaomo Yang, Jiajia Dong, Minfu Bai · 2023 · Frontiers in Genetics
29. PCSK9 genetic variants and risk of vascular and non-vascular diseases in Chinese and UK populations
    Michael Vaclav Holmes, Christiana Kartsonaki, Ruth Boxall, Kuang Lin, Nicola F. Reeve, Canqing Yu, Jun Lv, Derrick Bennett, Michael Hill, Ling Yang et al. · 2024 · European Journal of Preventive Cardiology
30. Ketogenic Diet as a Nutritional Metabolic Intervention for Obsessive–Compulsive Disorder: A Narrative Review
    Astrid Lounici, Ana Iacob, Katarzyna Hongler, Melina A. Mölling, Maria Drechsler, Lara Hersberger, Shebani Sethi, Undine Emmi Lang, Timur Liwinski · 2024 · Nutrients
31. Reappraisal of statin primary prevention trials: implications for identification of the statin-eligible primary prevention patient
    G.B. John Mancini, Arnold Ryomoto, Eunice Yeoh, Iulia Iatan, Liam R. Brunham, Robert Alexander Hegele · 2025 · European Journal of Preventive Cardiology
32. Is There a Need to Revise Goals in the Management of Dyslipidemias?
    David Sinning, Ulf Landmesser · 2019 · Current Cardiology Reports
33. Effects of active commuting to work for 12 months on cardiovascular risk factors and body composition
    Mahdi Sareban, Maria Dolores Fernandez La Puente de Battre, Bernhard Reich, Christian Marc Schmied, Martin Loidl, David Niederseer, Josef Niebauer · 2020 · Scandinavian Journal of Medicine and Science in Sports
34. Genetics, its role in preventing the pandemic of coronary artery disease
    Robert Roberts, Jacques Fair · 2021 · Clinical Cardiology
35. PCSK9 Inhibition-Based Therapeutic Approaches: An Immunotherapy Perspective
    Amir Abbas Momtazi‐Borojeni, Matteo Pirro, Suowen Xu, Amirhossein Sahebkar · 2021 · Current Medicinal Chemistry
36. Improving Stability Enhances In Vivo Efficacy of a PCSK9 Inhibitory Peptide
    Yuhui Zhang, Li Wang, Benjamin J. Tombling, Carmen Lammi, Yen‐Hua Huang, Yue Li, Martina Bartolomei, Bin Hong, David J. Craik, Conan K. L. Wang · 2022 · Journal of the American Chemical Society
37. The importance of considering LDL cholesterol response as well as cardiovascular risk in deciding who can benefit from statin therapy
    Handrean Soran, Jonathan D. Schofield, Paul N. Durrington · 2014 · Current Opinion in Lipidology
38. Genetically Determined TSH Level Within Reference Range Is Inversely Associated With Alzheimer Disease
    Gloria Hoi‐Yee Li, Ching‐Lung Cheung, Elaine Yun‐Ning Cheung, Wai-Chi Chan, K. C. B. Tan · 2021 · The Journal of Clinical Endocrinology & Metabolism
39. Mendelian randomization: a premature burial?
    George Davey Smith · 2015 · bioRxiv (Cold Spring Harbor Laboratory)
40. Myocardial ischemia and its complications
    Gregory A. Fishbein, Michael C. Fishbein, Jessica Wang, Louis Maximilian Buja · 2022 · Elsevier eBooks
41. Childhood Screening for Familial Hypercholesterolemia
    Samuel S. Gidding · 2023 · Journal of the American College of Cardiology
42. New Insights into Cardiovascular Diseases Treatment Based on Molecular Targets
    Armanda Wojtasińska, Joanna Kućmierz, Julita Tokarek, Jill Dybiec, Anna Rodzeń, Ewelina Młynarska, Jacek Rysz, Beata Franczyk · 2023 · International Journal of Molecular Sciences
43. The Risk-Benefit Paradigm vs the Causal Exposure Paradigm: LDL as a primary cause of vascular disease
    Peter Paul Toth, George Thanassoulis, Ken Williams, Curt Daniel Furberg, Allan D. Sniderman · 2014 · Journal of clinical lipidology
44. Budget Impact Analysis of PCSK9 Inhibitors for the Management of Adult Patients with Heterozygous Familial Hypercholesterolemia or Clinical Atherosclerotic Cardiovascular Disease
    Usha G. Mallya, Susan Boklage, Andrew Koren, Thomas E. Delea, C. Daniel Mullins · 2017 · PharmacoEconomics
45. Targeting the peptidase PCSK9 to reduce cardiovascular risk: Implications for basic science and upcoming challenges
    Toshiyuki Nishikido, Kausik Kumar Ray · 2019 · British Journal of Pharmacology
46. Association of CETP Gene Variants with Atherogenic Dyslipidemia Among Thai Patients Treated with Statin
    Pornpen Srisawasdi, Punyanuch Rodcharoen, Somlak Vanavanan, Anchalee Chittamma, Chonlaphat Sukasem, Chalitpon Na Nakorn, Charungthai Dejthevaporn, Martin H. Kroll · 2021 · Pharmacogenomics and Personalized Medicine
47. Effects of alirocumab on cardiovascular events and all-cause mortality: a systematic review and meta-analysis
    Wanting “Lisa” Wang, Zhaoqiang Feng, Jinghui Bai · 2021 · Reviews in Cardiovascular Medicine
48. Management of Familial Hypercholesterolemia in Hong Kong
    Miao Hu, Amanda J. Hooper, Frank M. VAN BOCKXMEER, Gerald Francis Watts, Juliana C.N. Chan, Brian Tomlinson · 2016 · Journal of Atherosclerosis and Thrombosis
49. The UK National Screening Committee’s position on child–parent screening for familial hypercholesterolaemia
    David S Wald, Dermot Neely · 2021 · Journal of Medical Screening
50. Association of cumulative low-density lipoprotein cholesterol exposure with vascular function
    Takayuki Yamaji, Farina Mohamad Yusoff, Shinji Kishimoto, Masato Kajikawa, Kenichi Yoshimura, Yukiko Nakano, Chikara Goto, Takahiro Harada, Aya Mizobuchi, Shunsuke Tanigawa et al. · 2023 · Journal of clinical lipidology
51. A Randomized, Double-Blind, Placebo-Controlled Clinical Trial on the Effect of a Dietary Supplement Containing Dry Artichoke and Bergamot Extracts on Metabolic and Vascular Risk Factors in Individuals with Suboptimal Cholesterol Levels
    Federica Fogacci, Marina Giovannini, Antonio Di Micoli, Giulia Fiorini, Elisa Grandi, Claudio Borghi, Arrigo F.G. Cicero · 2024 · Nutrients
52. Effect of Coenzyme Q10 on Physical Performance in Older Adults with Statin-Associated Asthenia: A Double-Blind, Randomized, Placebo-Controlled Clinical Trial
    Federica Fogacci, Marina Giovannini, Giuliano Tocci, Egidio Imbalzano, Claudio Borghi, Arrigo F.G. Cicero · 2024 · Journal of Clinical Medicine
53. In Situ Self‐Assembly of Artificial Topological Nanostructures Enhances In Vivo Efficacy of PCSK9 Inhibitory Peptides
    Qin Li, Zhaode Mu, Yuhan Dong, Zubin Ouyang, Jianli Zuo, Yijie Wu, Yuxuan Yang, Si Sun, Hong‐Wen Liang, Lijuan Bai · 2025 · Angewandte Chemie International Edition
54. Pathophysiology of bone remodelling cycle: Role of immune system and lipids
    Cinzia Parolini · 2025 · Biochemical Pharmacology
55. GLUT9 as a potential drug target for chronic kidney disease: Drug target validation by a Mendelian randomization study
    Masatoshi Ueda, Kenji Fukui, Naoyuki Kamatani, Shigeo Kamitsuji, Akira Matsuo, Tomohiko Sasase, Jun Nishiu, Mutsuyoshi Matsushita · 2023 · Journal of Human Genetics
56. The Potential Clinical Benefit of Lowering Lipoprotein(a)
    Brian A. Ference · 2022 · JAMA
57. Optimal Use of Plant Stanol Ester in the Management of Hypercholesterolemia
    Susanna Rosin, Ilkka Tapani Ojansivu, Aino Kopu, Malin Keto-Tokoi, Helena Gylling · 2015 · Cholesterol
58. Simplified algorithm to facilitate communication of familial hypercholesterolaemia: Figure 1
    Ulrich Laufs, Klaus Georg Parhofer · 2015 · European Heart Journal
59. Simulation of bempedoic acid and ezetimibe in the lipid-lowering treatment pathway in Austria using the contemporary SANTORINI cohort of high and very high risk patients
    Hermann Toplak, Aikaterini Bilitou, Hannes Franz Alber, Johann Auer, Martin Clodi, Christoph F. Ebenbichler, Evelyn Fließer-Görzer, Carmen Gelsinger, Ursula Hanusch, Bernhard H. Ludvik et al. · 2023 · Wiener klinische Wochenschrift
60. Effects of walking on epigenetic age acceleration: a Mendelian randomization study
    Guan-yi Chen, Chao Liu, Yu Xia, Pingxiao Wang, Zi-yue Zhao, Ao-yu Li, Chuqiao Zhou, Cheng Xiang, Jialin Zhang, Yi Zeng et al. · 2024 · Clinical Epigenetics
61. Challenges in the health economics of familial hypercholesterolemia
    Richard Norman, Gerald Francis Watts, William Weintraub, Samuel S. Gidding · 2016 · Current Opinion in Lipidology
62. Efficacy, safety, Low density lipoprotein cholesterol lowering, and calculated 10-year cardiovascular risk reduction of alirocumab and evolocumab in addition to maximal tolerated cholesterol lowering therapy: a post-commercialization study
    Parth K. Shah, Charles J. Glueck, Naila Goldenberg, Sarah Min, Chris Mahida, Ilana Miriam Schlam, Matan Rothschild, Ali Nor Huda, Ping Wang · 2017 · Lipids in Health and Disease
63. Proprotein convertase subtilisin/kexin type 9: an update on the cardiovascular outcome studies
    Nicola Ferri, Maria Francesca Greco, Alberto Corsini, Massimiliano Ruscica · 2020 · European Heart Journal Supplements
64. Nutritional Treatment in a Cohort of Pediatric Patients with Familial Hypercholesterolaemia: Effect on Lipid Profile
    Maria Elena Capra, Cristina Pederiva, Claudia Viggiano, Enrico Fabrizi, Giuseppe Banderali, Giacomo Biasucci · 2022 · Nutrients
65. A systematic review and meta-analysis of the prevalence of dyslipidaemia among adults in Malaysia
    Mohamed-Syarif Mohamed-Yassin, Norhidayah Rosman, Khairatul Nainey Kamaruddin, Hayatul Najaa Miptah, Noorhida Baharudin, Anis Safura Ramli, Suraya Abdul-Razak, Nai Ming Lai, GLOBALDYS Study Investigators · 2023 · Scientific Reports
66. Subtyping Severe Hypercholesterolemia by Genetic Determinant to Stratify Risk of Coronary Artery Disease
    Alexander S. F. Berry, L. Jones, E. Sijbrands, S. Gidding, M. Oetjens · 2023 · Arteriosclerosis, Thrombosis and Vascular Biology
67. Efficacy and safety of bempedoic acid lipid-lowering therapy: a systematic review and meta-analysis of randomized controlled trials
    Shravan Venkatraman, Saibal Das, Madhavi Eerike, Jerin Jose Cherian, Bhavani Shankara Bagepally · 2023 · European Journal of Clinical Pharmacology
68. Early Emotional Symptoms Predicting Carotid Atherosclerosis in Youth: Results From a Birth Cohort in Latin America
    Cristiano Tschiedel Belem da Silva, Maurício Scopel Hoffmann, Roberto Tofani SANT'ANNA, Fernando C. Wehrmeister, Helen Gonçalves, Isabel O. Oliveira, Paula Duarte de Oliveira, Antônio Marcos Vargas da Silva, Christian Kieling, Gisele Gus Manfro et al. · 2019 · Journal of the American Heart Association
69. How Low to Go With Lipid-Lowering Therapies in a Cost-effective and Prudent Manner
    Rhanderson N. Cardoso, Roger Scott Blumenthal, Stephen Louis Kopecky, Francisco Alejandro López-Jiménez, Seth Shay Martin · 2019 · Mayo Clinic Proceedings
70. Beginning With the End in Mind: The Case for Primordial and Primary Cardiovascular Prevention in Youth
    Sonali S. Patel, Stephen R. Daniels · 2020 · Canadian Journal of Cardiology
71. Polygenic modelling of treatment effect heterogeneity
    Zhi Ming Xu, Stephen Burgess · 2020 · Genetic Epidemiology
72. Modern strategy of diagnosis and treatment of children with heterozygous familial hypercholesterolemia
    Irina V. Leontyeva · 2020 · Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics)
73. A Combination of Single Nucleotide Polymorphisms is Associated with the Interindividual Variability of Cholesterol Bioavailability in Healthy Adult Males
    Charles Desmarchelier, Estelle Wolff, Catherine Defoort, Marion Nowicki, Pierre‐Emmanuel Morange, Marie‐Christine Alessi, René Valéro, Alain Nicolay, Denis Lairon, Patrick Borel · 2020 · Molecular Nutrition & Food Research
74. Genetics of Hypercholesterolemia: Comparison Between Familial Hypercholesterolemia and Hypercholesterolemia Nonrelated to LDL Receptor
    Estíbaliz Jarauta, Ana M. Bea, Victoria Marco-Benedí, Itziar Lamíquiz-Moneo · 2020 · Frontiers in Genetics
75. Integrating the Biology of Cardiovascular Disease into the Epidemiology of Economic Decision Modelling via Mendelian Randomisation
    Zanfina Ademi, Jedidiah I Morton, Danny Liew, Stephen James Nicholls, Sophia Zoungas, Brian A. Ference · 2022 · PharmacoEconomics
76. Imaging subclinical coronary atherosclerosis to guide lipid management, are we there yet?
    Pamela Piña, Daniel Lorenzatti, Rita Paula, Jonathan Daich, Aldo L. Schenone, Carlos A. Gongora, Mario Jorge Garcia, Michael Joseph Blaha, Matthew Jay Budoff, Daniel S. Berman et al. · 2022 · American Journal of Preventive Cardiology
77. A review of the clinical evidence related to early treatment of elevated LDL for cardiovascular primary prevention
    Kori Sauser Zachrison, Deborah A. Levine, Rodney A. Hayward · 2015 · BMJ Evidence-Based Medicine
78. Comparison of Lipid Profile in Patients With and Without Acute Myocardial Infarction
    Kheraj Mal, Ratan Kumar, Mishal Ejaz, Kiran Fatima, Faizan Shaukat · 2019 · Cureus
79. Disorders of Lipid Metabolism
    Clay F. Semenkovich, Anne Carol Goldberg, Ira J. Goldberg · 2016 · Elsevier eBooks
80. Biotechnology Approaches for the Treatment of Dyslipidemia
    Cinzia Parolini · 2020 · Cardiovascular Drugs and Therapy
81. Current perspectives on the use of statins in the treatment of dyslipidaemic patients: focus on pitavastatin
    Lale S Tokgözoğlu, José Luis Zamorano · 2020 · Drugs in Context
82. Mutations inNPC1L1and Coronary Heart Disease
    Oliver Weingärtner, Dieter Lütjohann, Shailendra B. Patel · 2015 · New England Journal of Medicine
83. Alta Prevalência de Dislipidemias em Crianças e Adolescentes: Oportunidade para Prevenção
    Leonardo Celeste Mangili · 2019 · Arquivos Brasileiros de Cardiologia
84. Using Genetic Variants in the Targets of Lipid Lowering Therapies to Inform Drug Discovery and Development: Current and Future Treatment Options
    Ference, Brian A. · 2019 · Clinical Pharmacology & Therapeutics
85. Lost Therapeutic Benefit of Delayed Low-Density Lipoprotein Cholesterol Control in Statin-Treated Patients and Cost-Effectiveness Analysis of Lipid-Lowering Intensification
    Clara Marquina, Jedidiah I Morton, Ella Zomer, Stella Talic, Sean Lybrand, David Thomson, Danny Liew, Zanfina Ademi · 2022 · Value in Health
86. Unveiling challenges in Mendelian randomization for gene–environment interaction
    Malka Gorfine, Conghui Qu, Ulrike Peters, Li Hsu · 2024 · Genetic Epidemiology
87. Reducing LDL-Cholesterol to Very Low Levels: Sailing Between Established Benefits and Potential Risks
    Stefania Angela Di Fusco, Massimo Volpe, Federico Nardi, Andrea Matteucci, Stefano Aquilani, G. Marino, Alessandro Aiello, Furio Colivicchi · 2025 · High Blood Pressure & Cardiovascular Prevention
88. Design and rationale of a randomized clinical trial assessing the effect of inclisiran on atherosclerotic plaque in individuals without previous cardiovascular event and without flow- limiting lesions identified in an in-hospital screening: The VICTORION-PLAQUE primary prevention trial
    Pruthvi C. Revaiah, Patrick W.J.C. Serruys, Yoshinobu Onuma, Daniele Andreini, Matthew Jay Budoff, Faisal Sharif, Ariel Chernofsky, Sheikh Vikarunnessa, Andrea J. Wiethoff, Denise P. Yates et al. · 2025 · American Heart Journal
89. Emerging therapies targeting lipoprotein(a): the next frontier in cardiovascular risk reduction
    Ibrahim S. Alhomoud · 2025 · Frontiers in Medicine
90. Individualized lipid-lowering therapy to further reduce residual cardiovascular risk
    Oliver Weingärtner, Dieter Lütjohann, Torsten Plösch, Albrecht Elsässer · 2016 · The Journal of Steroid Biochemistry and Molecular Biology
91. Alimentos funcionales y nutracéuticos en el tratamiento de la hipercolesterolemia: posicionamiento de la Sociedad Española de Arteriosclerosis 2023
    Pablo Pérez‐Martínez, Emilio Ros, Juan Pedro‐Botet, Fernando Civeira, Vicente Pascual, Cármen Garcés, Rosa Solà, Francisco Pérez‐Jiménez, José María Mostaza · 2023 · Clínica e Investigación en Arteriosclerosis
92. Lipid profile screening and ASCVD prevention
    Filippo Figorilli, Massimo Raffaele Mannarino, Amirhossein Sahebkar, Matteo Pirro · 2023 · Expert Review of Cardiovascular Therapy
93. Characterization and LDL‐C management in a cohort of high and very high cardiovascular risk patients: The PORTRAIT‐DYS study
    Cristina Gavina, Daniel Seabra, Carlos Aguíar, Anastassia Anastassopoulou, Carla Alexandra Costa Teixeira, Jorge Ruivo, É. Almeida, Leonor Luz Duarte, Ana Corte‐Real, Mariana Canelas‐Pais et al. · 2023 · Clinical Cardiology
94. Long-Term Evaluation of Lipid Profile Changes in Olympic Athletes
    Giuseppe Di Gioia, Lorenzo Buzzelli, Viviana Maestrini, Maria Rosaria Squeo, Erika Lemme, Sara Monosilio, Andrea Serdoz, Roberto Fiore, Domenico Zampaglione, Andrea Segreti et al. · 2024 · International Journal of Sport Nutrition and Exercise Metabolism
95. Statin Use in Special Populations for the Prevention of Cardiovascular Disease in Adults
    Maya S. Safarova, Spencer Frederick Weintraub, Katherine Anais Sadaniantz, Lara C. Kovell, Bruce A. Warden, Michael Seth Garshick, Paul Barton Duell, Eugenia Gianos · 2025 · Current Atherosclerosis Reports
96. Effect of Intermittent Fasting on Lipid Profile, Anthropometric and Hepatic Markers in Non-Alcoholic Fatty Liver Disease (NAFLD): A Systematic Review
    María Fernanda Castillo, Daniela Salgado-Canales, Marco A. Arrese, Francisco Barrera M., Dimitri P. Mikhailidis · 2024 · Current Vascular Pharmacology
97. Genetic contribution to lipid levels in early life based on 158 loci validated in adults: the FAMILY study
    Shanice Christie, Sébastien Robiou-du-Pont, Sonia Savitri Anand, Katherine Mary Morrison, Sarah Diana McDonald, Guillaume Paré, Stephanie A. Atkinson, Koon Kang Teo, David Meyre · 2017 · Scientific Reports
98. Evolocumab for the treatment of hypercholesterolemia
    Brian Tomlinson, Miao Hu, Yuzhen Zhang, Paul Chan, Zhong-Min Liu · 2017 · Expert Opinion on Biological Therapy
99. A Less than Provocative Approach for the Primary Prevention of CAD
    Robert Roberts, Jacques Fair · 2021 · Journal of Cardiovascular Translational Research
100. Association and its population heterogeneities between low-density lipoprotein cholesterol and all-cause and cardiovascular mortality: A population-based cohort study
     Jiapeng Lu, Haibo Zhang, Bowang Chen, Yang Yang, Jianlan Cui, Wei Xu, Lijuan Song, Hao Yang, Wenyan He, Yan Zhang et al. · 2024 · Chinese Medical Journal